Cabaletta Bio
RESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis
Generalized Myasthenia Gravis (gMG)
CABA-201
Phase 1
Phase 2
Myasthenia gravis (MG) is a rare autoimmune disorder characterized by autoantibody responses that cause defective transmission of signals at the neuromuscular junction, resulting in a distinctive pattern of weakness. Patients with generalized MG (gMG) typically experience symptoms associated with ocular disease in addition to weakness of many other voluntary muscle groups, including extremity, bulbar, and respiratory muscles. MG is considered a classic example of a B-cell mediated autoimmune disease. Currently, there are no curative treatments for MG. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with gMG. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.
Study Type : | Interventional |
Estimated Enrollment : | 12 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | RESET-MG: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Generalized Myasthenia Gravis |
Actual Study Start Date : | August 2024 |
Estimated Primary Completion Date : | September 2029 |
Estimated Study Completion Date : | September 2029 |
Arm | Intervention/treatment |
---|---|
Experimental: CABA-201 AChR Antibody-Positive Cohort AChR Antibody-Negative Cohort |
Biological: CABA-201 |
Ages Eligible for Study: | 18 Years to 70 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.